Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;24(1):57-71.
doi: 10.1038/s41573-024-01074-4. Epub 2024 Nov 15.

Senescence as a therapeutic target in cancer and age-related diseases

Affiliations
Review

Senescence as a therapeutic target in cancer and age-related diseases

Domhnall McHugh et al. Nat Rev Drug Discov. 2025 Jan.

Abstract

Cellular senescence is a stress response that restrains the growth of aged, damaged or abnormal cells. Thus, senescence has a crucial role in development, tissue maintenance and cancer prevention. However, lingering senescent cells fuel chronic inflammation through the acquisition of a senescence-associated secretory phenotype (SASP), which contributes to cancer and age-related tissue dysfunction. Recent progress in understanding senescence has spurred interest in the development of approaches to target senescent cells, known as senotherapies. In this Review, we evaluate the status of various types of senotherapies, including senolytics that eliminate senescent cells, senomorphics that suppress the SASP, interventions that mitigate senescence and strategies that harness the immune system to clear senescent cells. We also summarize how these approaches can be combined with cancer therapies, and we discuss the challenges and opportunities in moving senotherapies into clinical practice. Such therapies have the potential to address root causes of age-related diseases and thus open new avenues for preventive therapies and treating multimorbidities.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma Ltd. and Merck KGaA; owns equity in Geras Bio and share options in Myricx Pharma Ltd; is a named inventor in Medical Research Council (MRC) patents related to senolytic therapies; and has in the past received funding from Pfizer and Unity Biotechnology to work on senolytics. D.M. and J.G. are named inventors in an Imperial College patent related to senolytic therapies. I.D. declares no competing interest.

Similar articles

Cited by

References

    1. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965). - PubMed
    1. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961). This article is a pioneering study that defines the concept of cellular senescence. - PubMed
    1. d’Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003). - PubMed
    1. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997). - PubMed
    1. Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808–4818 (1999). - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources